<DOC>
	<DOC>NCT02356289</DOC>
	<brief_summary>The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a randomized, double-blind, placebo-controlled, sequential group, single ascending (oral) dose study in healthy volunteers aged 18-55 years.</brief_summary>
	<brief_title>Single Ascending Dose Study of MYK-461 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Normal body mass index (BMI) Normal LVEF Normal electrocardiogram (ECG) Females must not be breastfeeding and must be permanently sterilized or are postmenopausal. Any structural abnormalities on echocardiography Positive results of HIV test and/or seropositive for HCV or HBV.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
</DOC>